Smruthi Organics Ltd - Stock Valuation and Financial Performance

BSE: 540686 | NSE: | Pharmaceuticals & Drugs | Small Cap

Smruthi Organics Share Price

146.10 0.60 0.41%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Smruthi Organics

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Smruthi Organics stock performance -

mw4me loader
P/E Ratio (SA):
60.57
Market Cap:
167.2 Cr.
52-wk low:
117
52-wk high:
218.8

Is Smruthi Organics Ltd an attractive stock to invest in?

1. Is Smruthi Organics Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Smruthi Organics Ltd is a average quality company.

2. Is Smruthi Organics Ltd undervalued or overvalued?

The key valuation ratios of Smruthi Organics Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Smruthi Organics Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Smruthi Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Smruthi Organics:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Smruthi Organics Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -3.3%0.2%6.1%7.1%-0.6%15.1%13.5%27.7%16%6.7%-
Value Creation
Index
-1.2-1.0-0.6-0.5-1.00.10.01.00.2-0.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 93.776.673.879.497.3137131127133141125
Sales YoY Gr.--18.3%-3.6%7.6%22.7%41.2%-4.6%-3.5%5.4%5.8%-
Adj EPS -5.6-3.40.61.4-2.865.314.99.23.72.4
YoY Gr.-NANA126.2%-303.6%NA-12.3%183.5%-38%-60.1%-
BVPS (₹) 30.625.726.828.225.431.837.152.958.759.659.4
Adj Net
Profit
-6.4-3.80.71.6-3.26.9617.110.64.23
Cash Flow from Ops. 9.28.5149.25.112.121.422.82.212.1-
Debt/CF from Ops. 55.22.63.562.30.70.41.30.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 4.7%7.7%2.5%5.8%
Adj EPS NANA-11.2%-60.1%
BVPS7.7%18.6%17.1%1.5%
Share Price - 24.8% -15% 13.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
-16.9-11.92.35-10.52115.333.116.66.24.1
Op. Profit
Mgn %
1.76.114.412.63.412.512.122.61478.1
Net Profit
Mgn %
-6.9-512-3.354.613.57.932.2
Debt to
Equity
1.31.51.211.10.80.40.200.1-
Working Cap
Days
29333431725819415516313913215389
Cash Conv.
Cycle
10393999080665848819244

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 4.10%

Sales growth has been subdued in last 3 years 2.47%

Net Profit has been subdued in last 3 years -11.15%

Sales growth is not so good in last 4 quarters at -8.57%

Latest Financials - Smruthi Organics Ltd.

Standalone Consolidated
TTM EPS (₹) 2.4 -
TTM Sales (₹ Cr.) 125 -
BVPS (₹.) 59.4 -
Reserves (₹ Cr.) 57 -
P/BV 2.46 -
PE 60.57 -
From the Market
52 Week Low / High (₹) 117.00 / 218.80
All Time Low / High (₹) 21.70 / 419.35
Market Cap (₹ Cr.) 167
Equity (₹ Cr.) 11.5
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Smruthi Organics:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Smruthi Organics

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales9477747997137131127133141
Operating Expenses 927263699412111698115131
Manufacturing Costs10789111314121618
Material Costs66534349619183668091
Employee Cost 867891314121416
Other Costs 75531345856
Operating Profit 25111031715291810
Operating Profit Margin (%) 1.7%6.1%14.4%12.5%3.3%12.1%11.6%22.6%13.8%6.9%
Other Income 1001014110
Interest 5654443111
Depreciation 6544444445
Exceptional Items 0000000000
Profit Before Tax -9-623-5101224144
Tax -3-211-134730
Profit After Tax -6-412-37817104
PAT Margin (%) -6.6%-5.0%1.0%2.0%-3.3%5.0%6.4%13.5%7.8%2.9%
Adjusted EPS (₹)-5.4-3.30.61.4-2.86.07.415.09.13.6
Dividend Payout Ratio (%)0%0%0%0%0%11%14%20%33%55%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 35293132293642606768
Share Capital 4444444111111
Reserves 31262728253339495657
Minority Interest0000000000
Debt434031272928161035
Long Term Debt1317148622101
Short Term Debt302317192325141035
Trade Payables24151517223022141125
Others Liabilities 24222610477779
Total Liabilities 1261071028584101889288107

Fixed Assets

Gross Block868788309498104107114122
Accumulated Depreciation4452560646872768185
Net Fixed Assets41353230303032313337
CWIP 1111120112
Investments 0000000000
Inventories24181919212317182024
Trade Receivables26221921253625212837
Cash Equivalents 22222441612
Others Assets313029125611445
Total Assets 1261071028584101889288107

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 991495122123212
PBT -9-623-5101224145
Adjustment 101087777455
Changes in Working Capital 844-13-550-133
Tax Paid 000000-3-6-4-1
Cash Flow From Investing Activity -2-100-3-4-5-37-10
Capex -3-1-1-2-4-5-5-4-7-9
Net Investments 0000000013-1
Others 1011100110
Cash Flow From Financing Activity -6-8-14-9-2-5-17-7-12-2
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -24-4-4-2-40001
Interest Paid -5-6-5-4-4-4-3-1-1-1
Dividend Paid 000000-20-3-3
Others 1-6-5042-12-5-72
Net Cash Flow 2-10002-113-30
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)-16.15-11.832.415.03-10.4820.9721.4333.2316.276.11
ROCE (%)-4.6-0.019.5310.6-0.9621.542539.08217.39
Asset Turnover Ratio0.80.70.750.911.161.491.391.411.491.46
PAT to CFO Conversion(x)N/AN/A144.5N/A1.712.631.350.23
Working Capital Days
Receivable Days1031069586868285666884
Inventory Days117948683755855515257
Payable Days147134130117114104114995771

Smruthi Organics Ltd Stock News

Smruthi Organics Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Smruthi Organics on 28-Mar-2024 16:01 is ₹146.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Smruthi Organics stood at ₹167.2.
The latest P/E ratio of Smruthi Organics as of 28-Mar-2024 16:01 is 60.57.
The latest P/B ratio of Smruthi Organics as of 28-Mar-2024 16:01 is 2.46.
The 52-week high of Smruthi Organics is ₹218.8 and the 52-week low is ₹117.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Smruthi Organics is ₹124.8 ( Cr.) .

About Smruthi Organics Ltd

Smruthi Organics Ltd is a mid-size, public limited, API manufacturing company from Solapur, India. Smruthi Organics Ltd was established in1989 by qualified technocrats and has very good experience and reputation in the pharmaceutical industry for the supply of quality products. 

Their core competency is multi-step organic synthesis and large scale manufacturing of organic molecules. Their focus has always been API for the regulated markets. They have been part of successful contract manufacturing and custom synthesis agreements with leading European, American and Japanese customers. They are currently expanding our R&D to become a one-stop solution provider from concept to execution for all API including, but not restricted to, the following: 
  • Process Development
  • Process Optimization
  • Process Validation
  • Analytical Methods Validation
  • Regulatory Support and DMF Registrations
  • Commercial Manufacturing

Their constant endeavor to improve operations and systems has contributed to our growth. they encourage operational transparency with customers, which complements to confidence building for stronger relationships. Customer satisfaction is their highest priority and they constantly strive on optimizing delivery times of all their services.

Smruthi Organics Ltd facility is USFDA approved and European GMP certified for Carbidopa, Metformin HCL and Norfloxacin. It has successfully filed 4 European and US drug master files for different products.

Smruthi can manage a potential molecule's entire development life cycle up to commercialization through rigorous planning and proper execution. Smruthi can independently or in conjunction with the customer develop optimized synthesis process, perform scale-up and process validations, compile DMF and provide the customer with regulatory support for finished formulation dossier registration. The engagement can be either on an FTE or deliverables basis. We respect absolute confidentiality in such sensitive relationships enhancing smooth exchange of information.

Product range of the company includes:

API   
  • Amlodipine Base
  • Amlodipine Besilate
  • Carbidopa
  • Carvedilol
  • Chlorhexidine Base
  • Chlorhexidine Salts
  • Ciprofloxacin HCI
  • Clofibrate
  • Diloxanide Furoate
  • Enrofloxacin
  • Fenofibrate
  • Fluconazole
  • Iopomidol
  • Metformin HCI
  • Norfloxacin
  • Pefloxacin
  • S-Amlodipine
  • Nabumetone
Drug Intermediate
  • Nabumetone
  • Iopamidol / Iohexol
  • Montelukast
  • Iopamidol
  • Co-enzyme Q10
  • Atorvastatin
  • Carvedilol
  • Ciprofloxacin/Enrofloxacin
  • Perindopril
Achievements/ recognition:
  • The company’s quality systems and facilities are approved by USFDA, EU – GMP and ISO 9001:2000. 

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.